FAIR data policies can benefit biotech startups

Nature Biotechnology
July 31, 2023

To the life science startup on a fast-paced road to delivering new therapies or devices, data are arguably its most important asset. Establishing FAIR (findable, accessible, interoperable and reusable) data practices from the start can provide direct benefits throughout the lifetime of the company. Unlike large pharmaceutical companies that must undertake costly retrospective efforts to ‘FAIRify’ legacy data, startups are starting fresh and therefore have a unique and short-lived opportunity to chart a different course — positioning themselves to reduce program delays, innovate faster, enhance security and beyond.

Authored by Kate Hardy (MOMA, Therapeutics) and Stephan Heyse (Genedata, AG).